Human-specific Medical Research Techniques

Debate between Paul Scully and Charles Walker

Tuesday 4th July 2023 Westminster Hall

[Paul Scully]

I have talked to the hon. Gentleman about the three Rs. Essentially, nobody wants to be using animal testing where it is absolutely not needed. If innovation, such as computer models and new research, can find new ways of edging that out, why would any Government not want to do that? It has to be based on the evidence and the best science, and done on what is best for humankind, and that is what we will keep in mind. It is not done for the sake of animal testing in itself; it is very much evidence-based, as I said. That is why the current approach is to actively support and fund the development and dissemination of techniques that replace, reduce and refine the use of animals in research and to ensure that the UK has a robust regulatory system for licensing animal studies and enforcing legal standards.

Our legal framework is absolutely clear: animals are only ever used in science where there are no alternatives, where the number of animals used is the minimum needed to achieve the scientific benefit, and where the potential harm to animals is limited to that needed to achieve that scientific benefit. Under UK law, there are three main purposes for which animals may be used in science: for basic research to understand biological processes and systems; for translational research to understand how biological systems apply to real-world applications, such as the development of medicines; and to test the safety and efficacy of medicines and chemicals.

In each of those instances, the rationale is clear. Without basic research using animals, we would limit our ability to make the kind of scientific discoveries that could transform medicine for the better. Without translational research using animals, we would limit our ability to develop new medicines not just for humans, but for animals. Without testing those medicines using animals, we would not know whether those medicines were safe or effective for use in humans or animals, unnecessarily limiting the availability of medicines to treat life-threatening diseases. Many medicines that prove ineffective in humans are detected earlier through animal testing, too, enabling us to focus valuable research funds on medicines that will be effective.

To be clear, this Government are unapologetically ambitious in our mission to make Britain a science and technology superpower. We understand just how much world-leading research matters if we are to succeed and translate that success into real benefits for our people and our NHS. That means investing in the next generation of tools and technologies that provide alternatives to animal research, and it means, where animal research remains necessary, maintaining those rigorous principles to put ethics at the heart of that research. I thank Members once again for their insightful contributions to the debate, and I look forward to our working together in the months and years to come.

[Sir Charles Walker (in the Chair)]

Mr McCabe, you have two minutes.

 Orkambi and Cystic Fibrosis

Debate between Paul Scully and Charles Walker

Monday 19th March 2018 Westminster Hall

[Paul Scully]

I understand the hon. Gentleman’s position and concern, especially so when many people in Ireland in particular are cystic fibrosis sufferers, but I remind him that NHS England is the procurer, not the Government—it is done through that independent process.

[Mr Charles Walker (Broxbourne) (Con)]

I discussed this with my hon. Friend the Member for Meon Valley (George Hollingbery), who is in the Chamber. We decided that it is essential for Vertex and NHS England to be reasonable. There is common ground and a deal to be done. Both sides need to work towards that with the encouragement of the Minister and the Department of Health and Social Care.